Informação da revista
Vol. 41. Núm. 4.
Páginas 295-297 (Abril 2022)
Partilhar
Partilhar
Baixar PDF
Mais opções do artigo
Vol. 41. Núm. 4.
Páginas 295-297 (Abril 2022)
Editorial comment
Open Access
Infective endocarditis in Portugal – another piece added to the puzzle
Endocardite infecciosa em Portugal – outra peça adicionada ao puzzle
Visitas
...
Catarina de Sousaa,b
a Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina da Universidade de Lisboa, Portugal
b Lusíadas Knowledge Center, Lisboa, Portugal
Conteúdo relacionado
Rev Port Cardiol. 2022;41:283-9410.1016/j.repc.2021.02.027
Pedro Apolinário, Isabel Campos, Cátia Oliveira, Carina Silva, Carina Arantes, Juliana Martins, Alberto Salgado, Nuno Salomé, Carla Rodrigues, Paulo Medeiros, João Bizarro Pinho, Jorge Marques, Catarina Vieira
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Tabelas (1)
Table 1. Main results from prospective multicentric registries on IE.
Texto Completo

The reported low incidence of infective endocarditis (IE) ranging between 3 and 10 per 100 000 people1 is probably underestimated, as a diagnosis is often challenging. A temporal increase has been documented in some European countries such as United Kingdom (UK),2 Germany3 or Denmark.4 Recently, an analysis on IE in the Portuguese population5 over the last decade identified a similar trend. An aging population, an increasing rate of valve prosthesis and intracardiac device carriers, as well as the survival to adulthood of children with congenital heart disease all contribute to explaining the noted trends. Concomitantly, the extraordinary evolution in the imaging and microbiologic medical adjuvant techniques improve diagnostic ability in a clinical setting. Medical progress can also be a drawback, with an increasing rate of invasive medical procedures. Additionally, the impact of antibiotic prophylaxis restrictions defended by scientific guidelines since 20076 and 20091 on IE incidence is unclear. Concerns about physician compliance and evidence obtained mainly from retrospective observational studies do not enable a causal association to be made, even though an association has been found in the UK,7 Netherland8 and North America.9

Despite substantial improvements in its management (including antibiotic regimens and surgical intervention), complications and in-hospital mortality in IE continue to be substantial. This is in clear contrast to the trends observed with other cardiovascular entities such as acute coronary syndromes. Even though a significant variation exists among sites and countries, overall, in-hospital mortality is around 20%.10

Survival rates are highly dependent on the infectious agent, comorbid and clinical conditions. Onset to diagnosis time as well as onset to antibiotic/surgery time have been shown to have a significant impact on the outcome. Local team experience11 is a keystone, with essential collaboration between different specialties including cardiology, cardiac and non-cardiac imaging, internal medicine, infectious disease, microbiology and cardiac surgery warranted. The effect of an endocarditis team on survival has been shown by several groups and is indicated on the most recent scientific guidelines12 as an added value to clinical success.

In the last two decades, three major multicentric international prospective registries on infective endocarditis have been conducted – see Table 1. The most recent, EURO-ENDO13 was conducted after the publication of the most recent guidelines by the European Society of Cardiology in 2015. Portugal was a participant country and included 59 patients. When comparing the latter with the first registries, EURO-ENDO displayed older patients, with a higher rate of prosthetic or cardiac device-related IE. The surgical rate was similar and involved half the cohorts. Finally, a higher mortality rate was noted compared to the Euro Heart Survey.

Table 1.

Main results from prospective multicentric registries on IE.

  Euro Heart Survey14  ICE-Prospective15  EURO-ENDO13 
Period  2001  2000-2005  2016-2018 
Centers  92  58  156 (Portugal – 5) 
N (patients)  118  2781  3116 
Age – average, years old  56  57.9  59.2 
Female (%)  NA  32  31.1 
Native/Prosthetic/Cardiac Device-Related IE (%)  74/26/-  72/21/7  56.6/30.1/9.9 
Community/Nosocomial (%)  NA  71/14  65.6/32.9 
Most frequent infectious agents  Staphylococcus aureus (33%)  Staphylococcus aureus (31%)Viridans group streptococci – South America  Staphylococcus (44%) 
Blood cultures negative (%)  14  11  21 
Cardiac surgery (%)  52  48  51 
In-hospital death (%)  12.6  18  17.1 

ICE: International Collaborative Endocarditis; NA: not available.

In the last decade, the Journal has published three observational retrospective studies on IE patients hospitalized in Portuguese institutions, all from tertiary centers.16–18 Most national published observational studies derive so far from centers with cardiac surgery on site.19 In addition, all studies failed to address the issue of the impact of antibiotic prophylaxis restrictions.

In the current the Journal, a descriptive and inferential analysis of all patients admitted with IE between 1998 and 2013 at Hospital de Braga (a level II hospital with no cardiac surgery onsite) was undertaken by Apolinário et al.20 One hundred and seventy-three patients were identified. The authors describe the main clinical characteristics including presentation, comorbidities and main complications found, imaging and microbiologic findings as well as a management strategy. The main outcomes considered were cardiac surgery during the index episode and in-hospital all-cause death. They compare all variables in patients admitted before or after 2007, when the issue of antibiotic prophylaxis restrictions was first defended by international scientific guidelines. The first group included 93 patients (53.8% of the total cohort).

The following findings deserve to be highlighted in the present editorial:

  • 1.

    Patients admitted with IE are older which accounts for a higher rate of comorbidities and structural heart disease – this is a similar result to other international series.

  • 2.

    A significant proportion had cardiac valve prosthesis or cardiac device-related IE (18% before 2008 and 34.6% in the second group) – aging of the population and the increasing prevalence of degenerative valve disease, particularly aortic stenosis and mitral regurgitation have contributed to a rise in prosthetic cardiac valve and pacemaker implantations in developed countries with a repercussion on the rate of related IE.

  • 3.

    Negative blood cultures cases rose reaching up to 23% in the second group, which is an obstacle to an early diagnosis of these patients.

  • 4.

    Staphylococcus aureus is the most prevalent agent as in other contemporary series. Additionally, the emerging role of Enterococcus as an important infectious agent.

  • 5.

    The rate of patients who underwent cardiac surgery significantly increased after 2007 with an overall rate of 34%, which is comparable to the one displayed by Marques et al.21 from Hospital Garcia de Orta (32.8%), inferior nonetheless to the ones from level III Portuguese hospitals.16,17 Nevertheless, surgical rates in most Portuguese observational series continue to be inferior to the ones reported in the international registries (see Table 1).

  • 6.

    The in-hospital all-cause mortality (14.5%) is significantly inferior to the ones reported by most Portuguese observational studies.19 Also, a non-significant increase in in-hospital mortality was noted in the latter group. Hospital clustering levels, with more complex patients being referred to tertiary hospitals, leading to a referral bias could partially account for these findings. Long term all-cause death, on the other hand, revealed a significant rate of 38% and 47% at one and five years follow up. Regardless of all medical progress, IE continues to be a fatal disease.

In Portugal, physician compliance with guidelines regarding IE prophylaxis is in general an undetermined issue. Therefore, the described analysis by the authors serves the purpose of a temporal testimony more than a causal result of antibiotic prophylaxis restrictions on the outcomes.

Regardless of the limitations acknowledged by the authors, this is undoubtedly an important piece being added to the puzzle, on behalf of the less represented national non-tertiary hospital centers. Further national research is needed, particularly in a disease where diagnosis is dependent on local multidisciplinary expertise (clinical, imaging and microbiology) and the complex management should be individualized and not “a one size fits all”. From my perspective, it is crucial to further understand how early we are diagnosing IE in our centers, where the obstacles are, how functional the referral circuits to expert centers are, as well as access to multidisciplinary input (via IE heart team) and early corrective surgery. This national evidence will certainly reveal points for technical and organizational improvement that we as physicians should use to achieve a better outcome in this complex disease.

Funding

No external or internal funding was provided.

Conflicts of interest

The author has no conflicts of interest to declare.

References
[1]
G. Habib, B. Hoen, P. Tornos, et al.
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC).
Eur Heart J [Internet], 30 (2009), pp. 2369-2413
[2]
J. Mark, Dayer, S. Jones, et al.
An increase in the incidence of infective endocarditis in England since 2008: a secular trend interrupted time series analysis.
Lancet, 385 (2015), pp. 1219-1228
[3]
K. Keller, R.S. Bardeleben, M.A. Von Ostad, et al.
Temporal trends in the prevalence of infective endocarditis in Germany between 2005 and 2014.
Am J Cardiol [Internet], 119 (2017), pp. 317-322
[4]
A.D. Jensen, H. Bundgaard, J.H. Butt, et al.
Temporal changes in the incidence of infective endocarditis in Denmark 1997–2017: a nationwide study.
Int J Cardiol [Internet], 326 (2021), pp. 145-152
[5]
C. Sousa, P. Nogueira, F.J. Pinto.
Insight into the epidemiology of infective endocarditis in Portugal: a contemporary nationwide study from 2010 to 2018.
BMC Cardiovasc Disord [Internet], 21 (2021), pp. 138
[6]
W. Wilson, K.A. Taubert, M. Gewitz, et al.
Prevention of infective endocarditis: guidelines from the American Heart Association [Internet].
Circulation, 116 (2007), pp. 1736-1754
[7]
M.J. Dayer, S. Jones, B. Prendergast, et al.
Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis.
Lancet [Internet], 385 (2015), pp. 1219-1228
[8]
F.S. Brink, Van Den, M.J. Swaans, et al.
Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: a nationwide study in the Netherlands.
Eur Hear J - Qual Care Clin Outcomes, 3 (2017), pp. 141-147
[9]
S. Pant, N.N.J. Patel, N.N.J. Patel, et al.
Trends in infective endocarditis incidence microbiology, and valve replacement in the United States from 2000 to 2011.
J Am Coll Cardiol, 65 (2015), pp. 2070-2076
[10]
T.J. Cahill, B.D. Prendergast.
Infective endocarditis.
Lancet [Internet], 387 (2016), pp. 882-893
[11]
P. Tornos.
Endocarditis infecciosa: Una enfermedad grave e infrecuente que precisa ser tratada en hospitales con experiencia.
Rev Esp Cardiol, 58 (2005), pp. 1145-1147
[12]
G. Habib, P. Lancellotti, M.J. Antunes, et al.
2015 ESC guidelines for the management of infective endocarditis.
Eur Heart J [Internet], 36 (2015), pp. 3075-3128
[13]
G. Habib, P.A. Erba, B. Iung, et al.
Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.
Eur Heart J [Internet], 40 (2019), pp. 3222-3232
[14]
P. Tornos, B. Iung, G. Permanyer-Miralda, et al.
Infective endocarditis in Europe: lessons from the Euro heart survey.
Heart [Internet], 91 (2005), pp. 571-575
[15]
D.R. Murdoch, G.R. Corey, B. Hoen, et al.
Clinical presentation etiology and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study.
Ann Intern Med [Internet], 169 (2009), pp. 463-473
[16]
J.P. Ferreira, F. Gomes, P. Rodrigues, et al.
Left-sided infective endocarditis: analysis of in-hospital and medium-term outcome and predictors of mortality.
Rev Port Cardiol [Internet], 32 (2013), pp. 777-784
[17]
R. Ilhão Moreira, M. Coutinho Cruz, L. Moura Branco, et al.
Infective endocarditis: surgical management and prognostic predictors.
Rev Port Cardiol [Internet], 37 (2018), pp. 387-394
[18]
N. Guiomar, M. Vaz-da-Silva, D. Mbala, et al.
Cirurgia cardíaca na endocardite infeciosa e preditores da mortalidade intra-hospitalar.
Rev Port Cardiol [Internet], 39 (2020), pp. 137-149
[19]
C. de Sousa, R.M. Ribeiro, F.J. Pinto.
The burden of infective endocarditis in Portugal in the last 30 years – a systematic review of observational studies.
Rev Port Cardiol [Internet], 40 (2021), pp. 205-217
[20]
P. Apolinário, I. Campos, C. Oliveira, et al.
Endocardite infeciosa: epidemiologia e prognóstico.
Rev Port Cardiol, 41 (2022), pp. 283-294
[21]
A. Marques, I. Cruz, D. Caldeira, et al.
Risk factors for in-hospital mortality in infective endocarditis.
Arq Bras Cardiol, 114 (2020), pp. 1-8
Copyright © 2021. Sociedade Portuguesa de Cardiologia
Idiomas
Revista Portuguesa de Cardiologia

Receba a nossa Newsletter

Opções de artigo
Ferramentas
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.